Przeglądanie według Temat "chronic kidney disease"

Aktualnie wyświetlane 1 - 5 z 5

Clinical significance of serum interleukin-6 levels in patients with chronic kidney disease
(Publishing Office of the University of Rzeszow, 2024-09) Chokkavarapu, Renuka Charan; Bachireddy, Parimala; Billa, Vaibhavi Reddy; Vityala, Yethindra
Introduction and aim. Elevated levels of interleukin-6 (IL-6) in serum and kidney tissues are associated with the development and progression of chronic kidney disease (CKD). Although the role of pro-inflammatory cytokines, such as IL-6, in the development of cardiovascular complications is well studied, the relationship between serum IL-6 levels and CKD markers remains unclear. This study investigated the clinical significance of serum IL-6 levels in patients with CKD. Material and methods. Participants were divided into two groups based on estimated glomerular filtration rate (eGFR): group 1 (n=86) with eGFR >60 mL/min and group 2 (n=74) with eGFR <60 mL/min. The CKD Epidemiology Collaboration equation was used to calculate eGFR from serum creatinine and cystatin C levels to assess CKD severity. Results. Systolic blood pressure was higher in Group 2 than in Group 1 (138±22 mmHg vs. 129±19 mmHg; p<0.05). Serum IL-6 levels were also higher in group 2 (3.095 [interquartile range: 1.528–6.547] pg/mL) than in group 1 (1.711 [interquartile range: 0.920– 3.342] pg/mL; p <0.05). Serum IL-6 levels were strongly correlated with eGFR in multivariable-adjusted linear regression analysis. Conclusion. IL-6 levels increased in patients with CKD with an eGFR <60 mL/min, and this increase was associated with eGFR and diastolic blood pressure.
Effectiveness of novel iron regulators in the treatment of diabetic nephropathy
(Publishing Office of the University of Rzeszow, 2023-09) Banerjee, Dekai; Kaur, Ginpreet; Chatterjee, Bappaditya; Joshi, Hemant; Ramniwas, Seema; Tuli, Hardeep Singh
Introduction and aim. The novel advancements of upcoming iron regulators used to treat diabetic nephropathy have implicated a common manifestation of combination chelation therapy used to eliminate end-stage renal disease associated with inflammation and iron imbalance that is altered by renal iron absorption. However, iron accumulation in the clustered kidneys that filter blood may cause problems that affect diabetic blood sugar regulation. Material and methods. A well-designed method was employed to discover relevant research publications on iron chelators and their potential to treat diabetic nephropathy. “Iron chelators”, “diabetic nephropathy”, “end-stage renal disease”, and “chelation therapy” were searched in Google Scholar, Web of Science, PubMed, and EMBASE. Analysis of literature. Although the specific etiology and development have not been fully explored, emerging evidence on iron pathophysiology helps comprehend the pathogenesis of acute kidney damage and chronic kidney disease, which crucially provides novel iron chelation therapy techniques. Ferroptosis and hepcidin marker proteins increase oxidative/nitrifying stress and kidney injury. Iron chelator medicines including deferoxamine, deferasirox, and deferiprone were tested as prophylactic strategies. Conclusion. This article covers both preclinical and clinical aspects of iron chelators to avoid diabetic nephropathy, including novel iron therapies that must be reviewed when selecting dosing regimens.
Effects of vitamin D3 supplementation on lipid profile and renal indices in rat model of drug induced renal injury
(Publishing Office of the University of Rzeszow, 2024-12) Sonuga, Ayobola A.; Adeyanju, Motunrayo M.; Ladokun, Olusola A.; Sonuga, Oyebola O.
Introduction and aim. Renal injury is associated with decreased renal function, hypovitaminosis D, deranged calcium-phos phate metabolism and dyslipidemia, thus increasing risk for chronic kidney disease and cardiovascular diseases. However, re ports on the effects of vitamin D on drug induced renal injury are few. The aim was to investigate the possible role of vitamin D supplementation in reversing deranged lipid profile and renal function post drug induced renal injury. Material and methods. Wister male rats (36) were randomly divided into group 1, 2 and 3 (n=12). Single dose of Adriamycin was given to all except group 1(control) to induce renal injury. Group 2 left untreated, group 3 given vitamin D3 for 28 days. Serum urea, creatinine, total protein, total cholesterol (TC), triglycerides (TG), LDL-C, HDL, apolipoprotein (Apo) A and B were measured. C-reactive protein (CRP) and nitric oxide were assessed in kidney homogenate. Results. Vitamin D3 significantly brought down levels of serum creatinine, TC, LDL CRP, nitric oxide and increased the levels of Apo A, albumin, HDL. Serum urea, TG and Apo B in group 3 were not significantly different after vitamin D3 administration. His tological examination revealed improvement in glomerular messangialisation. Conclusion. Vitamin D3 may improve renal health, through its positive impact on dyslipidemia, inflammation, and oxidative stress in drug induced renal injury.
Efficacy of furosemide in patients with chronic kidney disease with residual renal functions in hemodialysis and non-hemodialysis patients
(Rzeszów University Press, 2025-03) Khan, Pathan Amanulla; Sana; Begum, Maimoona; Tabassum, Subiya; Fathima, Ayesha Farhath; Nagapurkar, Swati; Fatima, Naureen
Introduction and aim. Chronic kidney disease (CKD) affects kidney function, characterized by albuminuria or reduced estimat ed glomerular filtration rate (eGFR), and is influenced by factors such as etiology, pathogenesis, intensity, and progression. Ac cording to data from the literature, the efficacy of furosemide has not been much researched much in CKD patients. The study evaluates the efficacy in chronic kidney disease patients, regardless of hemodialysis, and compares its diuretic effect based on the administration route. Material and methods. A prospective observational study was conducted in a tertiary healthcare facility for 6 months (October 2021 to March 2022). 100 CKD patients who met the criteria were enrolled in the study. Data on study-relevant parameters, such as route of administration (ROA), hemodialysis frequency, hospital stay, blood urea, serum creatinine, sodium, and potas sium, were collected. Pearson’s chi-square test was used to evaluate the association between parameters. One-way ANOVA was applied to analyze the significant association between ROA and urine output. Results. Of all the study samples, 72% received intravenous furosemide and 28% received furosemide orally. There was a sig nificant difference in eGFR and urine output on admission and discharge days. There was an increase in urine output when the patient received furosemide and improvement in eGFR was found. A significant association was also observed between systolic blood pressure, sodium, and potassium. Conclusion. The study found no significant differences in furosemide efficacy in CKD patients, regardless of ROA, hospital stay, or frequency of hemodialysis, indicating similar effectiveness.
Prevalence, prescription patterns, and quality of life of anaemia in adults with chronic renal disease
(Publishing Office of the University of Rzeszow, 2023-12) Sandeep, Akkam; Elumalai, Karthikeyan; Williams, Helen; Salkapuram, Sunilkumar; Anandakumar, Shanmugam; Srinivasan, Sivaneswari
Introduction and aim. Anaemia is a chronic kidney disease (CKD) condition characterised by a decline in glomerular filtration rate (GFR) and impaired kidney function. The aim of this study was to assess the prevalence, prescribing patterns, and quality of life of anaemia in patients with chronic renal disease who were adults (>18 years of age) at a tertiary care hospital. Material and methods. Data on demographic characteristics, laboratory results, medication prescriptions, and quality of life assessments were collected. Statistical tests were performed to determine associations between anaemia prevalence and factors like age, gender, and CKD stage. The study included 132 patients, with a gender distribution of 89 men and 43 women. Results. The most frequently prescribed drugs are epoetin (15.06%), multivitamins (14.82%), iron (10.65%), folic acid (10.22%), calcium carbonate (8.17%), calcitriol (5.6%), and omeprazole (4.22%). The cardiovascular system, blood disorders, and blood-producing organs come after the gastrointestinal tract and metabolism in the first anatomical level of the ATC classification. Conclusion. It suggests hospital audits and recommendations for improved prescription practices. Further investigation into anaemia causes and drug class appropriateness is needed, and implementing improvements could potentially improve health outcomes.